The phase Ib TAKTIC study (NCT03959891) evaluated the efficacy of the AKT-1 inhibitor ipatasertib plus endocrine therapy plus or not palbociclib in patients with HR+/HER2− advanced BC. Here, AKT1 is linked to breast cancer.